Evidence map›Paper›PMID 40697330›Full record

ArticleJournal of hepatocellular carcinoma2025

Integrated Multi-Omics Profiling Identifies PDZ-Binding Kinase (PBK) as a Novel Prognostic Biomarker in Hepatocellular Carcinoma.

Juan Zhang, Yingyu Xu, Xiaojian Ni, Zhiyi Mao, Haitao Xiao, Maopei Chen, Youpei Lin, Jiaomeng Pan, Boheng Zhang, Lan Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juan Zhang *Department of Hepatobiliary Oncology, Liver Cancer Institute, Zhongshan Hospital; Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, People's Republic of China.ORCID 0009-0004-7549-8955
Yingyu Xu *Department of Biliary Surgery, Zhongshan Hospital, Fudan University; Biliary Tract Disease Center of Zhongshan Hospital, Fudan University; Biliary Tract Disease Institute, Fudan University; Cancer Center, Zhongshan Hospital, Fudan University; Shanghai Biliary Tract Minimal Invasive Surgery and Materials Engineering Research Center, Shanghai, People's Republic of China.
Xiaojian Ni *Department of Biliary Surgery, Zhongshan Hospital, Fudan University; Biliary Tract Disease Center of Zhongshan Hospital, Fudan University; Biliary Tract Disease Institute, Fudan University; Cancer Center, Zhongshan Hospital, Fudan University; Shanghai Biliary Tract Minimal Invasive Surgery and Materials Engineering Research Center, Shanghai, People's Republic of China.ORCID 0000-0003-0081-4162
Zhiyi Mao *Department of Biostatistics, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai, People's Republic of China.
Haitao XiaoDepartment of Traumatic Orthopedics, Hainan General Hospital, Haikou, People's Republic of China.
Maopei ChenDepartment of Hepatobiliary Oncology, Liver Cancer Institute, Zhongshan Hospital; Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, People's Republic of China.
Youpei LinDepartment of Hepatobiliary Surgery and Liver Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Jiaomeng PanDepartment of Hepatobiliary Surgery and Liver Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Boheng ZhangDepartment of Hepatobiliary Oncology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen Clinical Research Center for Cancer Therapy, Clinical Research Center for Precision medicine of abdominal tumor of Fujian Province, Xiamen City, Fujian Province, People's Republic of China.
Lan ZhangDepartment of Hepatobiliary Oncology, Liver Cancer Institute, Zhongshan Hospital; Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, People's Republic of China.
Xueying ZhengDepartment of Biostatistics, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai, People's Republic of China.
Guohe SongDepartment of Hepatobiliary Surgery and Liver Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Ningling GeDepartment of Hepatobiliary Oncology, Liver Cancer Institute, Zhongshan Hospital; Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) necessitates novel immunotherapeutic targets. PBK, a cancer/testis antigen (CTA), was identified as a pivotal hub gene influencing prognosis, tumor mutation burden (TMB), and immune microenvironment remodeling. Methods: PBK was prioritized using weighted gene co-expression network analysis (WGCNA) and differential expression screening in the TCGA-LIHC cohort, intersected with curated CTAs. Analyses assessed correlations with clinicopathological features (TNM stage, survival), genomic characterization (mutation frequencies), and functional validation via siRNA-mediated PBK knockdown in Huh7 cells (migration assay). Single-cell RNA sequencing (scRNA-seq) profiled of the tumor immune microenvironment. Results: PBK overexpression was significantly correlated with advanced TNM stage ( Conclusion: PBK synergistically drives HCC progression through three synergistic mechanisms: (1) promoting oncogenic mutation accumulation (eg,

Indexed as

bioinformaticscancer immunotherapyhepatocellular carcinomaPDZ-binding kinaseprognosis

Identifiers

PMID40697330
PMCPMC12279550

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.